**BE0003846632 - Common Stock **

We assign a fundamental rating of **1** out of 10 to **OXUR**. **OXUR** was compared to 49 industry peers in the **Biotechnology** industry. Both the profitability and financial health of **OXUR** have multiple concerns. **OXUR** has a expensive valuation and it also scores bad on growth

The profitability ratios for **OXUR** are negative, so there is not much use analyzing them.

ROA (-154.47%) VS Industry: 0% outperformed.

-154.47

121.18

Profit Margin (-2584.93%) VS Industry: 8% outperformed.

-470,040.00

78.59

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **OXUR**. No positive earnings are expected for the next year.

Based on estimates for the next 5 years, **OXUR** will show a quite strong growth in **Earnings Per Share**. The EPS will grow by **14.45%** on average per year.

When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

The earnings per share for **OXUR** have decreased by **-6.60%** in the last year.

Looking at the last year, **OXUR** shows a very negative growth in **Revenue**. The Revenue has decreased by **-45.72%** in the last year.

Measured over the past 5 years, **OXUR** shows a very negative growth in **Revenue**. The Revenue has been decreasing by **-30.79%** on average per year.

The **Revenue** is expected to decrease by **-14.87%** on average over the next 5 years. This is quite bad

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | N/A | N/A | -6.6% | 39.22% | 27.98% | -3.2% | 14.45% |

Revenue | -30.79% | -40.37% | -45.72% | -75.16% | -50.16% | -25.99% | -14.87% |

With a Debt to Equity ratio of **-7.86**, **OXUR** is one of the better performing companies in its industry. It outperforms **100%** of its industry peers.

Compared to an average industry Current Ratio of 3.06, **OXUR** is worse placed to pay its short term obligations than its industry peers. **93%** of its industry peers have a better Current Ratio.

When comparing the Quick Ratio of **OXUR** to the average industry Current Ratio of **2.73**, **OXUR** is less able to pay its short term obligations than its industry peers. **91%** of its industry peers have a better Quick Ratio.

Based on the Altman-Z score of **-7.78**, we must say that **OXUR** is in the distress zone and has some risk of bankruptcy.

When comparing the Altman-Z score of **OXUR** to the average industry Altman-Z score of **-0.32**, **OXUR** is less financially healthy than its industry peers. **93%** of its industry peers have a better Altman-Z score.

Debt/Equity (-7.86) VS Industry: 100% outperformed.

3.67

-7.86

Quick Ratio (1.22) VS Industry: 9% outperformed.

0.33

19.61

Current Ratio (1.23) VS Industry: 7% outperformed.

0.33

19.61

Altman-Z (-7.78) VS Industry: 7% outperformed.

-22.30

94.92

No dividends for **OXUR**!.

EBR:OXUR (8/10/2022, 7:00:00 PM)**+0.01 (+1.91%) **

GICS Sector | Health Care | ||

GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||

GICS Industry | Biotechnology | ||

Earnings (Last) | N/A N/A | Earnings (Next) | N/A N/A |

Ins Owners | N/A | Inst Owners | N/A |

Market Cap | 16.41M | Analysts | 44 |

PE | N/A | Fwd PE | N/A |

PEG (NY) | N/A | PEG (5Y) | N/A |

P/S | 14.54 | P/B | N/A |

EV/EBITDA | -0.7 |

ROA | -154.47% | ROE | N/A |

PM | -2584.93 | Asset Turnover | 0.06 |

EPS 1Y | -6.6% | EPS 3Y | N/A |

EPS 5Y | N/A | EPS growth Q2Q | 8.06% |

EPS Next Y | 39.22% | EPS Next 2Y | 27.98% |

EPS Next 3Y | -3.2% | EPS Next 5Y | 14.45% |

Revenue growth 1Y | -45.72% | Revenue growth 3Y | -40.37% |

Revenue growth 5Y | -30.79% | Revenue growth Q2Q | -2.93% |

Revenue Next Year | -75.16% | Revenue Next 2Y | -50.16% |

Revenue Next 3Y | -25.99% | Revenue Next 5Y | -14.87% |

Current Ratio | 1.23 | Quick Ratio | 1.22 |

Altman-Z | -7.78 | F-Score | 1 |

Debt/Equity | -7.86 |

Dividend Yield | N/A | Dividend Growth | N/A |

DP | N/A | Ex-Date | N/A |

*Find stocks with similar Fundamental rating on the EuroNext*

*Find the competitors with the best fundamentals on the EuroNext*

*Find the competitors with the best valuation on the EuroNext*

*Find the competitors with the best dividend on the EuroNext*